Read the full story by Timothy Dean, published by the Geisel School of Medicine.
Noted molecular biologist James Bliska is joining the Geisel School of Medicine as a Distinguished Professor in Microbiology and Immunology and senior lead faculty member of the Personalized Treatments for Cystic Fibrosis (CF) Cluster, a cross-Dartmouth group of investigators established to develop innovative, personalized medicine and treatments for CF and lung infections caused by opportunistic pathogens.
“I am very excited to have Dr. Bliska joining our faculty and leading the development of the Personalized Treatments for Cystic Fibrosis Cluster,” says Duane Compton, dean of Geisel. “I look forward to working with Dr. Bliska and Dr. Bruce Stanton, director of Geisel’s Lung Biology Center, in building an interdisciplinary team to develop a deeper understanding and more effective therapeutic strategies for disorders like CF, which involves a complex combination of genetic predisposition, epithelial cell biology, and pathogens.”
Bliska was formerly a professor of molecular genetics and microbiology at Stony Brook University, where he directed both the Center for Infectious Diseases and the Molecular and Cell Biology of Infectious Disease Training Program for graduate students. He begins work in Hanover this month.
“I’m very excited to join Geisel and the Department of Microbiology and Immunology,” says Bliska. “The highly collaborative environment and excellent scientists in that department, and the leadership of Bill Green, are well known to me and made this a great opportunity. The Lung Biology Center, headed by Bruce Stanton, is also a highly collaborative, interdisciplinary group of scientists working in the area that I’m interested in, and I’m thrilled to be a part of that, as well.”